| Literature DB >> 21565500 |
Tjeerd Barf1, Allard Kaptein, Sander de Wilde, Ruud van der Heijden, Richard van Someren, Dennis Demont, Carsten Schultz-Fademrecht, Judith Versteegh, Mario van Zeeland, Nicole Seegers, Bert Kazemier, Bas van de Kar, Maaike van Hoek, Jeroen de Roos, Henri Klop, Ruben Smeets, Claudia Hofstra, Jorrit Hornberg, Arthur Oubrie.
Abstract
MK2 kinase is a promising drug discovery target for the treatment of inflammatory diseases. Here, we describe the discovery of novel MK2 inhibitors using X-ray crystallography and structure-based drug design. The lead has in vivo efficacy in a short-term preclinical model.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21565500 DOI： 10.1016/j.bmcl.2011.04.018
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823